Fusion Risk Management Announces Strategic Growth Investment from Great Hill Partners
26.4.2023 15:00:00 EEST | Business Wire | Press release
Fusion Risk Management, Inc. (“Fusion” or the “Company”), a leading provider of cloud-based operational resilience, business continuity, and risk management software and services, today announced a strategic growth investment from Great Hill Partners, a leading growth-oriented private equity firm. The majority investment will allow Fusion to enhance its go-to-market and product innovation capabilities, while continuing to accelerate the pursuit of several attractive organic and inorganic growth opportunities. Existing investor Vista Equity Partners (“Vista”) will remain a significant minority shareholder in Fusion, along with Catalyst Investors and Level Equity Management. Financial terms of the transaction were not disclosed.
Fusion has grown rapidly in recent years as organizations in regulated and non-regulated end markets shift from reactive approaches to proactive, real-time frameworks that unite risk across employees, third parties, processes, and technologies. The Company’s leading platform empowers its diverse base of 400+ blue chip customers with the knowledge and workflows they need to better mitigate threats, minimize downtime, maintain operational resilience, and sustain critical operations in the face of unexpected crises such as pandemics, geopolitical events, natural disasters, cyber-attacks, and more.
“As the risk landscape continues to evolve, now more than ever businesses need an agile and flexible operational resilience framework to navigate disruption and drive sustainable growth," said Michael Campbell, CEO of Fusion Risk Management. “Today’s milestone is a testament to Fusion’s capabilities in delivering data-driven, actionable insights that enable customers to develop dynamic plans and proactively address the risks and disruptions that have become ‘business as usual.’ We’re confident that Great Hill will be an invaluable partner as we leverage their deep industry expertise and resources to further unlock the potential of our platform and accelerate our mission to make true business resiliency a reality.”
“Fusion is a clear leader in the risk management space, driving unparalleled value for its customers by providing them with the comprehensive tools they need to become more aware, prepared, and resilient,” said Chris Busby, Managing Director at Great Hill. “The Company fits the exact profile of the type of business we aim to invest in: high-growth companies that are driving transformative change in their industries. Leveraging our significant software and growth-investment experience, Fusion has tremendous potential to capitalize on opportunities ahead amid significant compliance and regulatory tailwinds and to continue deepening its strong, longstanding customer relationships. We’re excited to partner with Michael, the entire management team, and Vista to strengthen Fusion’s position at the forefront of operational resilience and risk management software.”
“Since our partnership began, Fusion and Vista have been focused on transforming the Company into a leading platform through product innovation and scaling its go-to-market capabilities to meet customers’ growing demand to build resilient organizations,” said René Yang Stewart, Co-Head of Vista’s Endeavor Fund and Senior Managing Director. “We are thrilled to continue this momentum by welcoming Great Hill Partners and embarking on the next chapter of Fusion’s growth trajectory.”
In addition to Fusion Risk Management, Great Hill Partners' portfolio of enterprise software companies includes eloomi, BigChange, Auvik, Varicent, Totango, and Intapp, among several others. Prior software investments include Reflexis Systems, Reward Gateway, PlanSource, ZoomInfo, and more.
William Blair & Company served as exclusive financial advisor to Fusion Risk Management. Kirkland & Ellis LLP served as legal advisor to Great Hill Partners and to Fusion.
About Fusion Risk Management, Inc.
Fusion Risk Management is a leading industry provider of cloud-based operational resilience software, encompassing business continuity and disaster recovery, risk management, information technology and security risk management, crisis and incident management, and more. Its solutions empower organizations to make data-driven decisions with a holistic, agile approach and enable them to deliver on their brand promise through disruption. For more information, visit www.fusionrm.com.
About Great Hill Partners
Founded in 1998, Great Hill Partners is a private equity firm targeting investments of $100 million to $500 million in high-growth companies across the software, digital commerce, financial technology, healthcare, and digital infrastructure sectors. With offices in Boston and London, Great Hill has raised over $12 billion of commitments and invested in more than 95 companies, establishing an extensive track record of building long-term partnerships with entrepreneurs and providing flexible resources to help middle-market companies scale. Great Hill has been recognized for its industry leadership, being ranked #3 in the 2022 HEC Paris-Dow Jones Mid-Market Buyout Performance Ranking, which evaluated fund performance of 563 leading private equity firms between 2009-2018. For more information, including a list of all Great Hill investments, visit www.greathillpartners.com.
About Vista Equity Partners
Vista is a leading global investment firm with more than $96 billion in assets under management as of December 31, 2022. The firm exclusively invests in enterprise software, data and technology-enabled organizations across private equity, permanent capital, credit and public equity strategies, bringing an approach that prioritizes creating enduring market value for the benefit of its global ecosystem of investors, companies, customers and employees. Vista's investments are anchored by a sizable long-term capital base, experience in structuring technology-oriented transactions and proven, flexible management techniques that drive sustainable growth. Vista believes the transformative power of technology is the key to an even better future – a healthier planet, a smarter economy, a diverse and inclusive community and a broader path to prosperity. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on Twitter, @Vista_Equity.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005272/en/
Contact information
For Fusion:
Terese Fernandez
Fusion Risk Management
917.640.1016
For Great Hill Partners:
Danya Al-Qattan / Zachary Tramonti / Kevin Siegel
greathill@fgsglobal.com
(212) 687-8080
For Vista Equity Partners:
Brian W. Steel
media@vistaequitypartners.com
(212) 804-9170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
